Beam Therapeutics BEAM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Beam Therapeutics (BEAM) Business Model and Operations Summary
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Key Insights
Beam Therapeutics (BEAM) Core Market Data and Business Metrics
Latest Closing Price
$18.48Market Cap
$1.85 BillionPrice-Earnings Ratio
-4.03Total Outstanding Shares
99.84 Million SharesTotal Employees
483Dividend
$0.23 Per Share QuarterlyIPO Date
February 6, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
26 Landsdowne Street, Cambridge, MA, 02139
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 2,744,053 Shares | 4.43 | 3/14/2025 | 12,163,727 Shares |
| 1,592,805 Shares | 6.27 | 2/28/2025 | 9,992,985 Shares |
| 1,257,943 Shares | 7.34 | 2/14/2025 | 9,237,141 Shares |
| 893,373 Shares | 11.21 | 1/31/2025 | 10,015,050 Shares |
| 1,462,839 Shares | 7.37 | 1/15/2025 | 10,786,501 Shares |
| 1,145,614 Shares | 8.58 | 12/31/2024 | 9,830,125 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-347.25 Million |
| Net Cash Flow From Financing Activities, Continuing | $7.74 Million |
| Net Cash Flow From Financing Activities | $7.74 Million |
| Net Cash Flow From Investing Activities, Continuing | $185.01 Million |
| Net Cash Flow, Continuing | $-154.50 Million |
| Net Cash Flow | $-154.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Depreciation and Amortization | $21.93 Million |
| Net Income/Loss Attributable To Parent | $-376.74 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Basic Earnings Per Share | $-4.58 |
| Income/Loss From Continuing Operations Before Tax | $-376.70 Million |
| Costs And Expenses | $440.22 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $75,000 |
| Other Comprehensive Income/Loss | $75,000 |
| Comprehensive Income/Loss | $-376.67 Million |
| Comprehensive Income/Loss Attributable To Parent | $-376.67 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $182.07 Million |
| Liabilities And Equity | $1.10 Billion |
| Cash | $850.70 Million |
| Wages | $21.57 Million |
| Fixed Assets | $111.41 Million |
| Assets | $1.10 Billion |
Historical Dividends
Current dividend: $0.23 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Jan 22, 2014 | Mar 3, 2014 | Feb 6, 2014 | $0.225 | Quarterly |
| Sep 19, 2013 | Dec 2, 2013 | Nov 6, 2013 | $0.225 | Quarterly |
| Jul 31, 2013 | Sep 3, 2013 | Aug 14, 2013 | $0.23 | Quarterly |
| Apr 24, 2013 | Jun 3, 2013 | May 8, 2013 | $0.225 | Quarterly |
| Jan 25, 2013 | Mar 1, 2013 | Feb 6, 2013 | $0.225 | Quarterly |
| Oct 4, 2012 | Dec 3, 2012 | Nov 7, 2012 | $0.205 | Quarterly |